Xilio Therapeutics (XLO) Projected to Announce Quarterly Earnings on Thursday

Xilio Therapeutics (NASDAQ:XLO) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.9350) per share and revenue of $4.92 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:30 AM ET.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Thursday, August 13th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.26. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%. The business had revenue of $18.69 million during the quarter, compared to analyst estimates of $12.72 million. On average, analysts expect Xilio Therapeutics to post ($3.17) EPS for the current fiscal year and ($1.74) EPS for the next fiscal year.

Xilio Therapeutics Stock Up 4.4%

Shares of XLO opened at $9.00 on Tuesday. The business’s 50-day moving average price is $8.75 and its 200-day moving average price is $8.50. Xilio Therapeutics has a twelve month low of $6.47 and a twelve month high of $11.75. The stock has a market cap of $59.22 million, a PE ratio of -5.49 and a beta of -0.13.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on XLO shares. Zacks Research raised shares of Xilio Therapeutics to a “hold” rating in a research note on Thursday, October 22nd. Raymond James Financial assumed coverage on shares of Xilio Therapeutics in a report on Wednesday, October 21st. They set an “outperform” rating and a $16.00 target price on the stock. Finally, Weiss Ratings upgraded shares of Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $16.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects.

Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.